Longeveron LLC Net Assets
Longeveron LLC net assets. Based on the latest financial reports, Longeveron LLC (LGVN) has net assets worth $14.71 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.49 Million) and total liabilities ($778.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Longeveron LLC (LGVN) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $14.71 Million |
| % of Total Assets | 94.98% |
| Annual Growth Rate | -2.58% |
| 5-Year Change | -84.85% |
| 10-Year Change | N/A |
| Growth Volatility | 645.15 |
Net Assets of Longeveron LLC (2018–2025)
Net assets of Longeveron LLC from 2018 to 2025. This chart illustrates how Longeveron LLC's net assets have evolved over time, based on quarterly financial data. See Longeveron LLC net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Longeveron LLC (2018–2025)
The table below shows the annual net assets of Longeveron LLC from 2018 to 2025. For live market cap and overall valuation, see Longeveron LLC stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $5.67 Million | -74.07% |
| 2024-12-31 | $21.89 Million | +224.68% |
| 2023-12-31 | $6.74 Million | -67.12% |
| 2022-12-31 | $20.50 Million | -45.26% |
| 2021-12-31 | $37.45 Million | +1813.80% |
| 2020-12-31 | $1.96 Million | -55.97% |
| 2019-12-31 | $4.45 Million | -34.77% |
| 2018-12-31 | $6.81 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Longeveron LLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13231100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Longeveron LLC Net Assets Breakdown (December 2025)
Longeveron LLC net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $22.00K | 0.39% |
| Other Components | $137.96 Million | 2431.08% |
| Total Equity | $5.67 Million | 100.00% |
Longeveron LLC Competitors by Market Cap
The table below lists competitors of Longeveron LLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BIONXT SOLUTIONS INC.
F:BXT
|
$23.62 Million |
|
Radiant Innovation
TWO:3373
|
$23.63 Million |
|
Acarix A/S
ST:ACARIX
|
$23.63 Million |
|
Culico Metals Inc.
V:CLCO
|
$23.65 Million |
|
CHINA NEW ENERGY LS-00025
F:9H5
|
$23.59 Million |
|
Eqva ASA
OL:EQVA
|
$23.58 Million |
|
Sikko Industries Limited
NSE:SIKKO
|
$23.57 Million |
|
Rubean AG
F:R1B
|
$23.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Longeveron LLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 21,887,000 to 5,675,000, a change of -16,212,000 (-74.1%).
- Net loss of 22,704,000 reduced equity.
- New share issuances of 4,980,000 increased equity.
- Other factors increased equity by 1,512,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-22.70 Million | -400.07% |
| Share Issuances | $4.98 Million | +87.75% |
| Other Changes | $1.51 Million | +26.64% |
| Total Change | $- | -74.07% |
Book Value vs Market Value Analysis
This analysis compares Longeveron LLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.51x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.42x to 5.51x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $4.28 | $1.78 | x |
| 2019-12-31 | $2.78 | $1.78 | x |
| 2020-12-31 | $1.16 | $1.78 | x |
| 2021-12-31 | $19.80 | $1.78 | x |
| 2022-12-31 | $9.78 | $1.78 | x |
| 2023-12-31 | $3.10 | $1.78 | x |
| 2024-12-31 | $1.47 | $1.78 | x |
| 2025-12-31 | $0.32 | $1.78 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Longeveron LLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -400.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1893.58%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 1.81x
- Recent ROE (-400.07%) is below the historical average (-161.86%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -92.99% | -296.84% | 0.20x | 1.54x | $-7.02 Million |
| 2019 | -83.71% | -66.09% | 0.53x | 2.38x | $-4.17 Million |
| 2020 | -190.14% | -66.10% | 0.61x | 4.72x | $-3.92 Million |
| 2021 | -45.51% | -1305.13% | 0.03x | 1.14x | $-20.79 Million |
| 2022 | -91.86% | -1541.33% | 0.04x | 1.34x | $-20.89 Million |
| 2023 | -317.65% | -3020.17% | 0.06x | 1.79x | $-22.09 Million |
| 2024 | -72.98% | -667.77% | 0.09x | 1.17x | $-18.16 Million |
| 2025 | -400.07% | -1893.58% | 0.12x | 1.81x | $-23.27 Million |
Industry Comparison
This section compares Longeveron LLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Longeveron LLC (LGVN) | $14.71 Million | -92.99% | 0.05x | $23.60 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Longeveron LLC
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; com… Read more